Directorate Change

RNS Number : 0541O

Syntopix Group plc

22 June 2010

 



Press Release

22 June 2010

Syntopix Group plc

("Syntopix" or "the Group")

Directorate Change

Syntopix Group plc (AIM:SYN), the speciality research and development company focused on the discovery of topical antimicrobials for healthcare and pharmaceutical applications, today announces the following Board change with immediate effect.

Alan Aubrey, who is the Chief Executive Officer of IP Group, Syntopix's largest shareholder and currently represents their interests on the Board, will step down as a Non-executive Director with immediate effect and will be replaced by Mike Townend (48), who is IP Group's Director of Capital Markets.

This announcement sets out the disclosures required pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies in respect of that appointment.

Mr Townend is currently a Non-executive Director of Modern Water plc, Revolymer Ltd. and Green Urban Transport plc.

There is no other information which needs to be discussed pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies.

- Ends -

For further information, please contact:

Syntopix Group plc
Dr Stephen Jones, Chief Executive Officer	[phone]
	www.syntopix.com

Zeus Capital Ltd
Alex Clarkson	Tel: [phone]
	www.zeuscapital.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins / Simone Elviss / Hannah Sharman	Tel: [phone]
[e-mail]	www.abchurch-group.com

- Ends -

 

END

 

 

BOABSGDLCBDBGGD